Febuxostat (BioDeep_00000858434)
代谢物信息卡片
Febuxostat
化学式: C16H16N2O3S (316.08815860000004)
中文名称: 非布索坦
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O
InChI: InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20)
描述信息
M - Musculo-skeletal system > M04 - Antigout preparations > M04A - Antigout preparations > M04AA - Preparations inhibiting uric acid production
D018501 - Antirheumatic Agents > D006074 - Gout Suppressants
C471 - Enzyme Inhibitor > C1637 - Xanthine Oxidase Inhibitor
C26170 - Protective Agent > C921 - Uricosuric Agent
同义名列表
1 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:31596
- KEGGdrug: D01206
- PubChem: 134018
- DrugBank: DB04854
- ChEMBL: CHEMBL1164729
- MeSH: Febuxostat
- CAS: 144060-53-7
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- C-Q Yan, C Liang, Z-R Lan, C Su, S-Y Xiong, Y-X Yang, J-M Chen, S-L Tang, J-S Huang, Z-H Zhang, M-J Luo, Z-H Xiao. Comparison of the efficacy of febuxostat vs. benzbromarone in the treatment of gout: a meta-analysis in Chinese gout patients.
European review for medical and pharmacological sciences.
2023 Dec; 27(24):11988-12003. doi:
10.26355/eurrev_202312_34797. [PMID: 38164861] - Xiaoqian Li, Yongqing Gu, Lihong Ren, Qingqing Cai, Yan Qiu, Jie He, Wei Qu, Wei Ji. Study of hispidulin in the treatment of uric acid nephropathy based on NF-κB signaling pathway.
Chemical biology & drug design.
2023 Oct; ?(?):. doi:
10.1111/cbdd.14367. [PMID: 37880153] - Mai Kakimoto, Moe Fujii, Ikumi Sato, Koki Honma, Hinako Nakayama, Sora Kirihara, Taketo Fukuoka, Shang Ran, Satoshi Hirohata, Kazuya Kitamori, Shusei Yamamoto, Shogo Watanabe. Antioxidant action of xanthine oxidase inhibitor febuxostat protects the liver and blood vasculature in SHRSP5/Dmcr rats.
Journal of applied biomedicine.
2023 06; 21(2):80-90. doi:
10.32725/jab.2023.009. [PMID: 37376883] - Hongtao Yang, Rong Li, Qing Li, Tiekun Yan, Yuefeng Li, Qun Huang, Shunya Uchida, Wenxiu Chang. Effects of febuxostat on delaying chronic kidney disease progression: a randomized trial in China.
International urology and nephrology.
2023 May; 55(5):1343-1352. doi:
10.1007/s11255-022-03437-5. [PMID: 36534221] - Yanfen Niu, Qiang Li, Caixia Tu, Na Li, Lihui Gao, Hua Lin, Zhenyu Wang, Zhihong Zhou, Ling Li. Hypouricemic Actions of the Pericarp of Mangosteen in Vitro and in Vivo.
Journal of natural products.
2023 01; 86(1):24-33. doi:
10.1021/acs.jnatprod.2c00531. [PMID: 36634312] - Wen Peng, Fuyao Liu, Lei Zhang, Liying Zhang, Jing Li. Design, synthesis, and evaluation of tricyclic compounds containing phenyl-tetrazole as XOR inhibitors.
European journal of medicinal chemistry.
2023 Jan; 246(?):114947. doi:
10.1016/j.ejmech.2022.114947. [PMID: 36462435] - Xin Zhang, Jie Cui, Junling Hou, Wenquan Wang. Research Progress of Natural Active Substances with Uric-Acid-Reducing Activity.
Journal of agricultural and food chemistry.
2022 Dec; 70(50):15647-15664. doi:
10.1021/acs.jafc.2c06554. [PMID: 36482671] - Na Yang, Bin Cao. Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Journal of clinical pharmacy and therapeutics.
2022 Dec; 47(12):2214-2222. doi:
10.1111/jcpt.13794. [PMID: 36403976] - Guangxing Shui, Zheyi Cai, Feng Wang, Ting Chen, Xueyuan Huang, Yun Cai, Xiuhua Mi. Simiao pill inhibits epithelial mesenchymal transition in a mouse model of chronic hyperuricemic nephropathy by inhibiting NLRP3 inflammasome activation.
BMC complementary medicine and therapies.
2022 Oct; 22(1):278. doi:
10.1186/s12906-022-03757-0. [PMID: 36271349] - Ayobami Oladele Afolabi, Tunmise Maryanne Akhigbe, Adeyemi Fatai Odetayo, Davinson Chuka Anyogu, Moses Agbomhere Hamed, Roland Eghoghosoa Akhigbe. Restoration of Hepatic and Intestinal Integrity by Phyllanthus amarus Is Dependent on Bax/Caspase 3 Modulation in Intestinal Ischemia-/Reperfusion-Induced Injury.
Molecules (Basel, Switzerland).
2022 Aug; 27(16):. doi:
10.3390/molecules27165073. [PMID: 36014309] - Jian-Hao Deng, Guo-Wei Zhong, Jia-Xing Zhang. Is febuxostat associated with higher risk of cardiovascular death than allopurinol in treating gout or asymptomatic hyperuricemia?.
Annals of palliative medicine.
2022 08; 11(8):2789-2791. doi:
10.21037/apm-22-618. [PMID: 35948476] - Satoru Mitsuboshi, Takahiro Niimura, Masaya Kanda, Shunsuke Ishida, Yoshito Zamami, Keisuke Ishizawa. Risk of Hematologic Events With Coadministration of Methotrexate and the Breast Cancer Resistance Protein Inhibitor Febuxostat.
The Annals of pharmacotherapy.
2022 08; 56(8):910-915. doi:
10.1177/10600280211055794. [PMID: 34726078] - Dongmei Liu, Binbin Zhou, Zhen Li, Zhuojun Zhang, Xiaojuan Dai, Zongfei Ji, Huiyong Chen, Ying Sun, Lindi Jiang. Effectiveness of benzbromarone versus febuxostat in gouty patients: a retrospective study.
Clinical rheumatology.
2022 Jul; 41(7):2121-2128. doi:
10.1007/s10067-022-06110-5. [PMID: 35229198] - Tunlanut Sapankaew, Kunlawat Thadanipon, Narisa Ruenroengbun, Kamolpat Chaiyakittisopon, Atiporn Ingsathit, Pawin Numthavaj, Nathorn Chaiyakunapruk, Gareth McKay, John Attia, Ammarin Thakkinstian. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.
BMC nephrology.
2022 06; 23(1):223. doi:
10.1186/s12882-022-02850-3. [PMID: 35739495] - Nicola Dalbeth, Anthony J Doyle, Karen Billington, Greg D Gamble, Paul Tan, Kieran Latto, Thrishila Parshu Ram, Ravi Narang, Rachel Murdoch, David Bursill, Borislav Mihov, Lisa K Stamp, Anne Horne. Intensive Serum Urate Lowering With Oral Urate-Lowering Therapy for Erosive Gout: A Randomized Double-Blind Controlled Trial.
Arthritis & rheumatology (Hoboken, N.J.).
2022 06; 74(6):1059-1069. doi:
10.1002/art.42055. [PMID: 34927391] - Jiahe Fan, Shiwei Sun, Chaoyi Lv, Zhizhou Li, Mengru Guo, Yichen Yin, Hui Wang, Wei Wang. Discovery of mycotoxin alternariol as a potential lead compound targeting xanthine oxidase.
Chemico-biological interactions.
2022 Jun; 360(?):109948. doi:
10.1016/j.cbi.2022.109948. [PMID: 35430257] - Giovambattista Desideri, Marek Rajzer, Martijn Gerritsen, Michael T Nurmohamed, Cristina Giannattasio, Anne-Kathrin Tausche, Claudio Borghi. Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study.
European heart journal. Cardiovascular pharmacotherapy.
2022 05; 8(3):236-242. doi:
10.1093/ehjcvp/pvaa144. [PMID: 33410912] - Xiang Yu, Mingjia Gu, Yiye Zhu, Lixiang Zhang, Wei Kong, Yanqin Zou. Efficacy of Urate-Lowering Therapy in Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials.
Clinical therapeutics.
2022 May; 44(5):723-735.e6. doi:
10.1016/j.clinthera.2022.03.014. [PMID: 35610080] - Lloyd Wei Tat Tang, Tino Woon Huai Cheong, Eric Chun Yong Chan. Febuxostat and its major acyl glucuronide metabolite are potent inhibitors of organic anion transporter 3: Implications for drug-drug interactions with rivaroxaban.
Biopharmaceutics & drug disposition.
2022 Apr; 43(2):57-65. doi:
10.1002/bdd.2310. [PMID: 35088420] - Atsushi Tanaka, Shigeru Toyoda, Toru Kato, Hisako Yoshida, Shuichi Hamasaki, Masato Watarai, Tomoko Ishizu, Shinichiro Ueda, Teruo Inoue, Koichi Node. Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial.
RMD open.
2022 04; 8(1):. doi:
10.1136/rmdopen-2022-002226. [PMID: 35410947] - Shaoling Zheng, Pui Y Lee, Yukai Huang, Weiming Deng, Zhixiang Huang, Qidang Huang, Shuyang Chen, Tianwang Li. Clinical characteristics of juvenile gout and treatment response to febuxostat.
Annals of the rheumatic diseases.
2022 04; 81(4):599-600. doi:
10.1136/annrheumdis-2021-221762. [PMID: 34930759] - Hiroshi Kataoka, Toshio Mochizuki, Mamiko Ohara, Yuki Tsuruta, Naomi Iwasa, Rie Yoshida, Ken Tsuchiya, Kosaku Nitta, Kenjiro Kimura, Tatsuo Hosoya. Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study.
Scientific reports.
2022 03; 12(1):3784. doi:
10.1038/s41598-022-07737-9. [PMID: 35260678] - Yuliya Afinogenova, Abhijeet Danve, Tuhina Neogi. Update on gout management: what is old and what is new.
Current opinion in rheumatology.
2022 03; 34(2):118-124. doi:
10.1097/bor.0000000000000861. [PMID: 34907116] - Shunichiro Tsukamoto, Naohito Okami, Takayuki Yamada, Kengo Azushima, Takahiro Yamaji, Sho Kinguchi, Kazushi Uneda, Tomohiko Kanaoka, Hiromichi Wakui, Kouichi Tamura. Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis.
Clinical rheumatology.
2022 Mar; 41(3):911-919. doi:
10.1007/s10067-021-05956-5. [PMID: 34642880] - Young Ho Lee, Gwan Gyu Song. Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.
International journal of clinical pharmacology and therapeutics.
2022 Mar; 60(3):159-166. doi:
10.5414/cp204097. [PMID: 34779393] - Takahiro Miura, Akihiro Sakuyama, Lusi Xu, Jiahe Qiu, Asako Namai-Takahashi, Yoshiko Ogawa, Masahiro Kohzuki, Osamu Ito. Febuxostat ameliorates high salt intake-induced hypertension and renal damage in Dahl salt-sensitive rats.
Journal of hypertension.
2022 02; 40(2):327-337. doi:
10.1097/hjh.0000000000003012. [PMID: 34495901] - Guang Ma, Min Li, Wei Teng, Zhaohui He, Xiaojv Zhai, Zhenhua Xia. Febuxostat combined with hydration for the prevention of contrast-induced nephropathy in hyperuricemia patients undergoing percutaneous coronary intervention: A CONSORT-compliant randomized controlled trial.
Medicine.
2022 Jan; 101(4):e28683. doi:
10.1097/md.0000000000028683. [PMID: 35089218] - Seokwoo Park, Jung Pyo Lee, Dong Ki Kim, Yon Su Kim, Chun Soo Lim. Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression.
PloS one.
2022; 17(2):e0264627. doi:
10.1371/journal.pone.0264627. [PMID: 35226683] - Liudmyla V Khimion, Oleksandr A Burianov, Iryna M Nayshtetik, Svitlana O Rotova, Svitlana I Smiyan, Svitlana V Danyliuk, Viktoriia V Trofanchuk. POSSIBILITIES OF RENOPROTECTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERURICEMIA.
Wiadomosci lekarskie (Warsaw, Poland : 1960).
2022; 75(5 pt 1):1059-1063. doi:
10.36740/wlek202205102. [PMID: 35758478] - Isil Gazioglu, S Evrim Kepekci Tekkeli, Angela Tartaglia, Ceylin Aslan, Marcello Locatelli, Abuzar Kabir. Simultaneous determination of febuxostat and montelukast in human plasma using fabric phase sorptive extraction and high performance liquid chromatography-fluorimetric detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2022 Jan; 1188(?):123070. doi:
10.1016/j.jchromb.2021.123070. [PMID: 34920289] - Navni Sharma, Sandeep Kumar, Garima Joshi, Deepak Choudhary. Formulation and Characterization of Febuxostat Loaded Nanostructured Lipid Carriers (NLCs) - Gel for Topical Treatment of Gout.
Recent patents on nanotechnology.
2022; 16(3):250-258. doi:
10.2174/1872210515666210415114118. [PMID: 33858317] - Kenya Kusunose, Hisako Yoshida, Atsushi Tanaka, Hiroki Teragawa, Yuichi Akasaki, Yoshihiro Fukumoto, Kazuo Eguchi, Haruo Kamiya, Kazuomi Kario, Hirotsugu Yamada, Masataka Sata, Koichi Node. Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study.
Hypertension research : official journal of the Japanese Society of Hypertension.
2022 Jan; 45(1):106-115. doi:
10.1038/s41440-021-00752-9. [PMID: 34657137] - Yushang Tang, Tongqiang Liu, Qiuping Cai, Minwen Zhao. The Effects of Febuxostat on Urine NGAL and Urine KIM-1 in Patients with Hyperuricemia.
Journal of healthcare engineering.
2022; 2022(?):6028611. doi:
10.1155/2022/6028611. [PMID: 35419185] - Satoshi Suzuki, Akiomi Yoshihisa, Tetsuro Yokokawa, Atsushi Kobayashi, Takayoshi Yamaki, Hiroyuki Kunii, Kazuhiko Nakazato, Akihiro Tsuda, Tatsunori Tsuda, Toshiyuki Ishibashi, Ichiro Konno, Osamu Yamaguchi, Hirofumi Machii, Naoki Nozaki, Takeshi Niizeki, Takuya Miyamoto, Yasuchika Takeishi. Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial.
The Journal of international medical research.
2021 Dec; 49(12):3000605211062770. doi:
10.1177/03000605211062770. [PMID: 34914568] - Ertao Jia, Haiqiong Zhu, Hongling Geng, Yadong Wang, Li Zhong, Shangwen Liu, Feng Lin, Jianyong Zhang. Effect of alkalized urine on renal calculi in patients with gout: a protocol for a placebo-controlled, double-blinded randomized controlled trial.
Trials.
2021 Oct; 22(1):743. doi:
10.1186/s13063-021-05721-8. [PMID: 34702311] - Meijiao Wang, Yi Zhang, Min Zhang, Haichang Li, Chengping Wen, Ting Zhao, Zhijun Xie, Jing Sun. The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis.
Annals of palliative medicine.
2021 10; 10(10):10327-10337. doi:
10.21037/apm-21-1564. [PMID: 34498481] - Raul Fernandez-Prado, Alberto Ortiz. Verinurad/Febuxostat and Nephrotoxicity.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2021 09; 78(3):468. doi:
10.1053/j.ajkd.2021.03.029. [PMID: 34126127] - Subuhi Kaul, Manasvi Gupta, Dhrubajyoti Bandyopadhyay, Adrija Hajra, Prakash Deedwania, Edward Roddy, Mamas Mamas, Allan Klein, Carl J Lavie, Gregg C Fonarow, Raktim K Ghosh. Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2021 Sep; 21(5):499-512. doi:
10.1007/s40256-020-00459-1. [PMID: 33369719] - Ertao Jia, Yanying Zhang, Wukai Ma, Bo Li, Hongling Geng, Li Zhong, Xueming Yao, Jingjing Xie, Yuya Xiao, Yubao Jiang, Xia Qiu, Min Xiao, Xiang Cui, Jiaxin Wei, Jianyong Zhang. Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial.
Rheumatology (Oxford, England).
2021 09; 60(9):4199-4204. doi:
10.1093/rheumatology/keaa908. [PMID: 33404656] - Austin G Stack, Fredrik Erlandsson, Robert Terkeltaub. In Reply to 'Verinurad/Febuxostat and Nephrotoxicity'.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2021 09; 78(3):468-469. doi:
10.1053/j.ajkd.2021.05.009. [PMID: 34126126] - Melonie K Sriranganathan, Ophir Vinik, Jordi Pardo Pardo, Claire Bombardier, Christopher J Edwards. Interventions for tophi in gout.
The Cochrane database of systematic reviews.
2021 08; 8(?):CD010069. doi:
10.1002/14651858.cd010069.pub3. [PMID: 34379791] - Alaa Eldin Elsayed Elsisi, Samia Salem Sokar, Marwa Fouad Shalaby, Sally El-Sayed Abu-Risha. Nephroprotective effects of febuxostat and/or mirtazapine against gentamicin-induced nephrotoxicity through modulation of ERK 1/2, NF-κB and MCP1.
Expert review of clinical pharmacology.
2021 Aug; 14(8):1039-1050. doi:
10.1080/17512433.2021.1933435. [PMID: 34030558] - Tomohiko Ishikawa, Toshinari Takahashi, Tetsuya Taniguchi, Tatsuo Hosoya. Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout.
Expert opinion on pharmacotherapy.
2021 Aug; 22(11):1397-1406. doi:
10.1080/14656566.2021.1918102. [PMID: 33926357] - Haiyang Yang, Xueyan Li, Gang Li, Huating Huang, Wenning Yang, Xiaoquan Jiang, Muli Sen, Jingjing Liu, Yang Liu, Yanli Pan, Guopeng Wang. Accurate quantitative determination of affinity and binding kinetics for tight binding inhibition of xanthine oxidase.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2021 Jul; 139(?):111664. doi:
10.1016/j.biopha.2021.111664. [PMID: 34243606] - Weijing Zhang, Di Zhao, Min Wu, Weiyu Chen, Zhibin Jin, Huayong Zhang. Ultrasound Evaluation of Three Outcome Domains in the Follow-up of Urate-Lowering Therapy in Gout: An Observational Study.
Ultrasound in medicine & biology.
2021 06; 47(6):1495-1505. doi:
10.1016/j.ultrasmedbio.2021.02.020. [PMID: 33785225] - Galal Magdy, Ahmed F Abdel Hakiem, Fathalla Belal, Ahmed M Abdel-Megied. A novel quality by design approach for development and validation of a green reversed-phase HPLC method with fluorescence detection for the simultaneous determination of lesinurad, febuxostat, and diflunisal: Application to human plasma.
Journal of separation science.
2021 Jun; 44(11):2177-2188. doi:
10.1002/jssc.202100016. [PMID: 33773042] - Anushree Tiku, David W Johnson, Sunil V Badve. Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease.
Current opinion in nephrology and hypertension.
2021 05; 30(3):346-352. doi:
10.1097/mnh.0000000000000699. [PMID: 33767063] - Api Chewcharat, Yawen Chen, Charat Thongprayoon, Andrew M Harrison, Michael A Mao, Wisit Cheungpasitporn. Febuxostat as a renoprotective agent for treatment of hyperuricaemia: a meta-analysis of randomised controlled trials.
Internal medicine journal.
2021 May; 51(5):752-762. doi:
10.1111/imj.14814. [PMID: 32149437] - John Elmer Cabang Quilisadio, Evelyn Osio Salido, Ester Gonzales Penserga. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
Modern rheumatology.
2021 May; 31(3):755-761. doi:
10.1080/14397595.2020.1800557. [PMID: 32701037] - A K Tausche. [Gout].
Der Internist.
2021 May; 62(5):513-525. doi:
10.1007/s00108-021-00987-1. [PMID: 33721041] - Austin G Stack, David Han, Ronald Goldwater, Susanne Johansson, Nalina Dronamraju, Jan Oscarsson, Eva Johnsson, Joanna Parkinson, Fredrik Erlandsson. Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.
The Journal of clinical endocrinology and metabolism.
2021 04; 106(5):e2347-e2356. doi:
10.1210/clinem/dgaa748. [PMID: 33075806] - Austin G Stack, Nalina Dronamraju, Joanna Parkinson, Susanne Johansson, Eva Johnsson, Fredrik Erlandsson, Robert Terkeltaub. Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2021 04; 77(4):481-489. doi:
10.1053/j.ajkd.2020.09.009. [PMID: 33130235] - Diana I Jalal, Glenn M Chertow. Urate Lowering With Combination Therapy in CKD: Reason for Optimism or Einstein's Definition of Insanity?.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2021 04; 77(4):478-480. doi:
10.1053/j.ajkd.2020.11.007. [PMID: 33568321] - Yichao Xu, Jinliang Chen, Dandan Yang, Yin Hu, Xinhua Hu, Bo Jiang, Zourong Ruan, Honggang Lou. Development of LC-MS/MS determination method and backpropagation artificial neural networks pharmacokinetic model of febuxostat in healthy subjects.
Journal of clinical pharmacy and therapeutics.
2021 Apr; 46(2):333-342. doi:
10.1111/jcpt.13285. [PMID: 33201513] - Galal Magdy, Fathalla F Belal, Ahmed M Abdel-Megied, Ahmed F Abdel Hakiem. Micelle-Enhanced conventional and synchronous spectrofluorimetric methods for the simultaneous determination of lesinurad and febuxostat: Application to human plasma.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2021 Mar; 248(?):119239. doi:
10.1016/j.saa.2020.119239. [PMID: 33310619] - Kazuki Yoshida, Hyon K Choi, Daniel H Solomon. Medications for gout and its comorbidities: mutual benefits?.
Current opinion in rheumatology.
2021 03; 33(2):145-154. doi:
10.1097/bor.0000000000000784. [PMID: 33399398] - See Y Choi, Seung W Choi, Sunggun Lee, Min W So, Ji S Oh, Doo-Ho Lim. Efficacy and tolerability of febuxostat in gout patients on dialysis.
Internal medicine journal.
2021 Mar; 51(3):348-354. doi:
10.1111/imj.14776. [PMID: 32043690] - Katsuhito Miyazawa, Dan Nakai, Yuka Nakamura, Takanori Tatsuno, Shinya Inoue, Yusuke Nakazawa, Yasuhito Ishigaki. Effects of the xanthine oxidase inhibitor, febuxostat, on the expression of monocyte chemoattractant protein-1 and synchronous genes in MDCK cells treated with calcium oxalate monohydrate crystals.
International journal of urology : official journal of the Japanese Urological Association.
2021 03; 28(3):339-345. doi:
10.1111/iju.14450. [PMID: 33393162] - Dinko Rekić, Susanne Johansson, Jacob Leander. Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight.
Clinical pharmacokinetics.
2021 03; 60(3):319-328. doi:
10.1007/s40262-020-00943-6. [PMID: 32951150] - Meida Fan, Jian Liu, Bingcheng Zhao, Xinyu Wu, Xuefeng Li, Jieruo Gu, Naomi Schlesinger. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
Clinical rheumatology.
2021 Feb; 40(2):683-692. doi:
10.1007/s10067-020-05272-4. [PMID: 32654080] - Kazuomi Kario, Masafumi Nishizawa, Mari Kiuchi, Arihiro Kiyosue, Fumishi Tomita, Hiroshi Ohtani, Yasuhisa Abe, Hideyo Kuga, Satoshi Miyazaki, Takatoshi Kasai, Makiko Hongou, Takanori Yasu, Jin Kuramochi, Yoshihiro Fukumoto, Satoshi Hoshide, Ichiro Hisatome. Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia.
Journal of clinical hypertension (Greenwich, Conn.).
2021 02; 23(2):334-344. doi:
10.1111/jch.14153. [PMID: 33400348] - Ichiro Hisatome, Peili Li, Junichiro Miake, Fikri Taufiq, Endang Mahati, Nani Maharani, Sulistiyati Bayu Utami, Masanari Kuwabara, Udin Bahrudin, Haruaki Ninomiya. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
Circulation journal : official journal of the Japanese Circulation Society.
2021 01; 85(2):130-138. doi:
10.1253/circj.cj-20-0406. [PMID: 33342914] - Arrigo F G Cicero, Federica Fogacci, Raffaele Ivan Cincione, Giuliano Tocci, Claudio Borghi. Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients.
Medical principles and practice : international journal of the Kuwait University, Health Science Centre.
2021; 30(2):122-130. doi:
10.1159/000512178. [PMID: 33040063] - Eman H Nadwa, George N B Morcos, Nagwan M Salama, Amani N Shafik. Comparing the Effects of Febuxostat and Allopurinol in an Animal Model of Metabolic Syndrome.
Pharmacology.
2021; 106(9-10):564-572. doi:
10.1159/000516495. [PMID: 34182567] - Nicole Nourié, Hussein Nassereddine, Hiba Azar. An Unusual Course of a 2,8-Dihydroxyadeninuria Crystalline Nephropathy Secondary to Adenine Phosphoribosyltransferase Deficiency.
Nephron.
2021; 145(5):503-507. doi:
10.1159/000516281. [PMID: 34044400] - Ratchaya Lertnawapan, Kanon Jatuworapruk. Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
Clinical rheumatology.
2021 Jan; 40(1):255-262. doi:
10.1007/s10067-020-05262-6. [PMID: 32607660] - Ahmed E Amer, Ahmed R El-Sheakh, Mohamed F Hamed, Hassan A El-Kashef, Manar A Nader, George S G Shehatou. Febuxostat attenuates vascular calcification induced by vitamin D3 plus nicotine in rats.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2021 Jan; 156(?):105580. doi:
10.1016/j.ejps.2020.105580. [PMID: 33010420] - Yoshiro Tanaka, Tomohisa Nagoshi, Akira Yoshii, Yuhei Oi, Hirotake Takahashi, Haruka Kimura, Keiichi Ito, Yusuke Kashiwagi, Toshikazu D Tanaka, Michihiro Yoshimura. Xanthine oxidase inhibition attenuates doxorubicin-induced cardiotoxicity in mice.
Free radical biology & medicine.
2021 01; 162(?):298-308. doi:
10.1016/j.freeradbiomed.2020.10.303. [PMID: 33470212] - Asmaa Mohamed Abdel-Aziz, Nashwa Fathy Gamal El-Tahawy, Medhat Atta Salah Abdel Haleem, Mostafa Mouard Mohammed, Ahmed Issam Ali, Yasmine F Ibrahim. Amelioration of testosterone-induced benign prostatic hyperplasia using febuxostat in rats: The role of VEGF/TGFβ and iNOS/COX-2.
European journal of pharmacology.
2020 Dec; 889(?):173631. doi:
10.1016/j.ejphar.2020.173631. [PMID: 33031799] - Bishoy Kamel, Garry G Graham, Sophie L Stocker, Zhixin Liu, Kenneth M Williams, Jane E Carland, Kevin D Pile, Richard O Day. A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjects.
British journal of clinical pharmacology.
2020 12; 86(12):2486-2496. doi:
10.1111/bcp.14357. [PMID: 32386239] - Isla S Mackenzie, Ian Ford, George Nuki, Jesper Hallas, Christopher J Hawkey, John Webster, Stuart H Ralston, Matthew Walters, Michele Robertson, Raffaele De Caterina, Evelyn Findlay, Fernando Perez-Ruiz, John J V McMurray, Thomas M MacDonald. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Lancet (London, England).
2020 11; 396(10264):1745-1757. doi:
10.1016/s0140-6736(20)32234-0. [PMID: 33181081] - Karl T Clebak, Ashley Morrison, Jason R Croad. Gout: Rapid Evidence Review.
American family physician.
2020 11; 102(9):533-538. doi:
NULL. [PMID: 33118789] - Minna Lehtisalo, Jenni E Keskitalo, Aleksi Tornio, Outi Lapatto-Reiniluoto, Feng Deng, Taina Jaatinen, Jenni Viinamäki, Mikko Neuvonen, Janne T Backman, Mikko Niemi. Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin.
Clinical and translational science.
2020 11; 13(6):1236-1243. doi:
10.1111/cts.12809. [PMID: 32453913] - Benjamin Rohn, Wiebke Jansing, Felix S Seibert, Thiemo Pfab, Okan Cinkilic, Jürgen Paßfall, Sven Schmidt, Nina Babel, Frederic Bauer, Timm H Westhoff. Association of hyperuricemia and serum uric acid lowering therapy with mortality in hemodialysis patients.
Renal failure.
2020 Nov; 42(1):1067-1075. doi:
10.1080/0886022x.2020.1835674. [PMID: 33076736] - Lotfollah Davoodi, Seyed Mohammad Abedi, Ebrahim Salehifar, Reza Alizadeh-Navaei, Hamed Rouhanizadeh, Ghasemali Khorasani, Seyed Jalal Hosseinimehr. Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial.
International journal of clinical practice.
2020 Nov; 74(11):e13600. doi:
10.1111/ijcp.13600. [PMID: 32603531] - Christopher Estiverne, David B Mount. The Management of Gout in Renal Disease.
Seminars in nephrology.
2020 11; 40(6):600-613. doi:
10.1016/j.semnephrol.2020.12.007. [PMID: 33678314] - Amira M Abo-Youssef, Hassan Afify, Amany A Azouz, Hanaa M Abdel-Rahman, Ashraf B Abdel-Naim, Shady Allam. Febuxostat attenuates testosterone-induced benign prostatic hyperplasia in rats via inhibiting JAK/STAT axis.
Life sciences.
2020 Nov; 260(?):118414. doi:
10.1016/j.lfs.2020.118414. [PMID: 32926929] - Pitchai Balakumar, Ali Alqahtani, Noohu Abdulla Khan, Nanjaian Mahadevan, Sokkalingam A Dhanaraj. Mechanistic insights into hyperuricemia-associated renal abnormalities with special emphasis on epithelial-to-mesenchymal transition: Pathologic implications and putative pharmacologic targets.
Pharmacological research.
2020 11; 161(?):105209. doi:
10.1016/j.phrs.2020.105209. [PMID: 32979505] - Mohammed M Maresh, Rania R Abdelaziz, Tarek M Ibrahim. Febuxostat mitigates concanavalin A-induced acute liver injury via modulation of MCP-1, IL-1β, TNF-α, neutrophil infiltration, and apoptosis in mice.
Life sciences.
2020 Nov; 260(?):118307. doi:
10.1016/j.lfs.2020.118307. [PMID: 32841665] - Bhavesh Babulal Gabani, Neeraj Kumar Saini, Ravi Kumar Jairam, Pavan Shrinivas, Ravi Kumar Trivedi, Nuggehally R Srinivas, Ramesh Mullangi. Simultaneous determination of colchicine and febuxostat in rat plasma: Application in a rat pharmacokinetic study.
Biomedical chromatography : BMC.
2020 Nov; 34(11):e4939. doi:
10.1002/bmc.4939. [PMID: 32614997] - Anna M Hu, Jamie N Brown. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
Clinical rheumatology.
2020 Nov; 39(11):3287-3294. doi:
10.1007/s10067-020-05079-3. [PMID: 32418037] - Yan Zhang, Runzhou Pan, Yao Xu, Yongcai Zhao. Treatment of refractory gout with TNF-α antagonist etanercept combined with febuxostat.
Annals of palliative medicine.
2020 Nov; 9(6):4332-4338. doi:
10.21037/apm-20-2072. [PMID: 33302685] - Wei Chen, Naya Huang, Haiping Mao, Xiao Yang, Qian Zhou, Lanping Jiang, Jun Ding, Qiong Feng, Xueqing Yu. Rationale and design for Lowering-hyperUricaemia treatment on cardiovascular outcoMes In peritoNeal diAlysis patients: a prospective, multicentre, double-blind, randomised controlled trial (LUMINA).
BMJ open.
2020 10; 10(10):e037842. doi:
10.1136/bmjopen-2020-037842. [PMID: 33040002] - Jian-An Pan, Hao Lin, Chang-Qian Wang, Jun-Feng Zhang, Jun Gu. Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia.
Heart and vessels.
2020 Oct; 35(10):1446-1453. doi:
10.1007/s00380-020-01619-8. [PMID: 32430700] - Huang Wen, Zhu Yongling, Zheng Shuying, Wang Jiali, Zhao Yanling. Effect of febuxostat on renal function in patients from South China with CKD3 diabetic nephropathy.
Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia.
2020 Oct; 42(4):393-399. doi:
10.1590/2175-8239-jbn-2019-0091. [PMID: 32701116] - Ruixia Sun, Jie Lu, Hui Li, Xiaoyu Cheng, Ying Xin, Changgui Li. Evaluation of febuxostat initiation during an acute gout attack: A prospective, randomized clinical trial.
Joint bone spine.
2020 Oct; 87(5):461-466. doi:
10.1016/j.jbspin.2020.03.017. [PMID: 32302693] - Hrafnhildur Linnet Runolfsdottir, Runolfur Palsson, Inger M Sch Agustsdottir, Olafur S Indridason, Jennifer Li, Myriam Dao, Bertrand Knebelmann, Dawn S Milliner, Vidar O Edvardsson. Kidney Transplant Outcomes in Patients With Adenine Phosphoribosyltransferase Deficiency.
Transplantation.
2020 10; 104(10):2120-2128. doi:
10.1097/tp.0000000000003088. [PMID: 31880754] - Marie Barrientos-Regala, Renelene A Macabeo, Rosemarie Ramirez-Ragasa, Noemi S Pestaño, Felix E R Punzalan, Bernadette Tumanan-Mendoza, Rafael R Castillo. The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis.
Journal of cardiovascular pharmacology.
2020 10; 76(4):461-471. doi:
10.1097/fjc.0000000000000871. [PMID: 32675751] - Bin Fan, Ping Zhang, Xiaoyu Li. Efficacy and safety of Febuxostat Versus Allopurinol in Hyperuricemic patients with or without Gout: A meta-analysis.
Neuro endocrinology letters.
2020 Oct; 41(4):195-204. doi:
NULL. [PMID: 33307654] - Akira Sezai, Satoshi Unosawa, Makoto Taoka, Shunji Osaka, Hisakuni Sekino, Masashi Tanaka. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.
2020 Aug; 26(4):202-208. doi:
10.5761/atcs.oa.19-00162. [PMID: 31748427] - Mabel Aoun, Rayane Salloum, Antoine Dfouni, Ghassan Sleilaty, Dania Chelala. A formula predicting the effective dose of febuxostat in chronic kidney disease patients with asymptomatic hyperuricemia based on a retrospective study and a validation cohort
.
Clinical nephrology.
2020 Aug; 94(2):61-69. doi:
10.5414/cn109867. [PMID: 32589132] - Sil-Ling Pruis, Yunjoo Karris Jeon, Fiona Pearce, Bernard Yu-Hor Thong, Mohamed Ismail Abdul Aziz. Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.
Journal of medical economics.
2020 Aug; 23(8):838-847. doi:
10.1080/13696998.2020.1757456. [PMID: 32301360] - Eikan Mishima, Takayasu Mori, Yoko Nakajima, Takafumi Toyohara, Koichi Kikuchi, Yoshitsugu Oikawa, Tetsuro Matsuhashi, Yasuhiro Maeda, Takehiro Suzuki, Masataka Kudo, Sadayoshi Ito, Eisei Sohara, Shinichi Uchida, Takaaki Abe. HPRT-related hyperuricemia with a novel p.V35M mutation in HPRT1 presenting familial juvenile gout.
CEN case reports.
2020 08; 9(3):210-214. doi:
10.1007/s13730-020-00459-9. [PMID: 32128695] - Michael Toprover, Binita Shah, Cheongeun Oh, Talia F Igel, Aaron Garza Romero, Virginia C Pike, Fatmira Curovic, Daisy Bang, Deana Lazaro, Svetlana Krasnokutsky, Stuart D Katz, Michael H Pillinger. Initiating guideline-concordant gout treatment improves arterial endothelial function and reduces intercritical inflammation: a prospective observational study.
Arthritis research & therapy.
2020 07; 22(1):169. doi:
10.1186/s13075-020-02260-6. [PMID: 32653044] - Marta Novella-Navarro, Jose Luis Cabrera-Alarcon, Cesar Diaz-Torne, Francisco Aramburu-Muñoz, Iustina Janta, Maria Carmen Ortega de la O, Alejandro Prada-Ojeda, Luis Sala-Icardo, Ana Urruticoechea-Arana, Paloma García de la Peña Lefebvre, Enrique Calvo-Aranda. A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3.
Rheumatology international.
2020 Jul; 40(7):1081-1087. doi:
10.1007/s00296-020-04517-4. [PMID: 31982955] - Y F Ibrahim, R R Fadl, Sae Ibrahim, M F Gayyed, Ama Bayoumi, Mmm Refaie. Protective effect of febuxostat in sepsis-induced liver and kidney injuries after cecal ligation and puncture with the impact of xanthine oxidase, interleukin 1β, and c-Jun N-terminal kinases.
Human & experimental toxicology.
2020 Jul; 39(7):906-919. doi:
10.1177/0960327120905957. [PMID: 32054342] - Cheryl K T Chua, Peter P Cheung, Amelia Santosa, Anita Y N Lim, Gim Gee Teng. Burden and management of gout in a multi-ethnic Asian cohort.
Rheumatology international.
2020 Jul; 40(7):1029-1035. doi:
10.1007/s00296-019-04475-6. [PMID: 31758246] - Sang-Hyon Kim, So-Yeon Lee, Ji-Min Kim, Chang-Nam Son. Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis.
The Korean journal of internal medicine.
2020 07; 35(4):998-1003. doi:
10.3904/kjim.2018.423. [PMID: 30959584] - Yueh-Lung Peng, You-Lin Tain, Chien-Te Lee, Yi-Hsn Yang, Yaw-Bin Huang, Yen-Hsia Wen, Chien-Ning Hsu. Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease.
Scientific reports.
2020 07; 10(1):10734. doi:
10.1038/s41598-020-67026-1. [PMID: 32612180]
